Zentrum Fur Klinische Studien Dr. Hanusch GmbH

At Zentrum Fur Klinische Studien Dr. Hanusch GmbH in Vienna, the clinical trial portfolio is strongly focused on cardiovascular research, especially conditions linked to high risk of heart attack, stroke, and other major heart-related events. Studies are exploring new ways to reduce atherosclerotic cardiovascular disease, improve outcomes in people with elevated lipoprotein(a), and better manage broader cardiovascular disease.

• Testing new therapies aimed at lowering the risk of major cardiovascular events in people with elevated lipoprotein(a) and established heart disease risk.
• Evaluating treatments designed to prevent heart attack, stroke, and urgent coronary procedures in adults at high cardiovascular risk.
• Assessing whether newer approaches can improve cardiovascular protection beyond standard lipid-lowering care.

This area includes research on prevention as well as treatment effectiveness, with a clear goal of reducing serious complications in patients who have not yet had a prior heart attack or stroke.

The site also conducts studies in nutritional and metabolic diseases, with a particular emphasis on obesity, overweight, type 2 diabetes mellitus, and related cardiometabolic risk. These trials are examining whether newer therapies can support weight management while also improving heart and kidney outcomes.

• Investigating treatments for adults living with obesity or overweight who also face increased cardiovascular risk.
• Studying therapies for type 2 diabetes to see whether they can reduce major heart events alongside standard care.
• Exploring options that may help protect both cardiovascular and kidney health in people with metabolic disease.

Overall, the research reflects a growing focus on therapies that address both metabolic control and long-term protection against serious complications, including cardiovascular events and kidney outcomes.